Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stages of Endometrial Cancer
After endometrial cancer has been diagnosed, tests are done to find out if cancer cells have spread within the uterus or to other parts of the body.The process used to find out whether the cancer has spread within the uterus or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. Certain tests and procedures are used in the staging process. A hysterectomy (an operation in which the uterus is removed) will usually be done to help find out how far the cancer has spread.The following procedures may be used in the staging process: Pelvic exam: An exam of the vagina, cervix, uterus, fallopian tubes, ovaries, and rectum. The doctor or nurse inserts one or two lubricated, gloved fingers of one hand into the vagina and the other hand is placed over the lower abdomen to feel the size, shape, and position of the uterus and ovaries. A speculum is also
Cervical Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Endometrial Cancer
Related Summaries Note: Other PDQ summaries containing information related to endometrial (uterine corpus) cancer include the following: Uterine Sarcoma Treatment Endometrial Cancer Screening Endometrial Cancer Prevention Statistics Note: Estimated new cases and deaths from endometrial (uterine corpus) cancer in the United States in 2010:[ 1 ] New cases: 43,470. Deaths: 7,950. Cancer of the ...
Cervical Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - General Information About Gestational Trophoblastic Disease
Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception.Gestational trophoblastic disease (GTD) develops inside the uterus from tissue that forms after conception (the joining of sperm and egg). This tissue is made of trophoblast cells and normally surrounds the fertilized egg in the uterus. Trophoblast cells help connect the fertilized egg to the wall of the uterus and form part of the placenta (the organ that passes nutrients from the mother to the fetus).Sometimes there is a problem with the fertilized egg and trophoblast cells. Instead of a healthy fetus developing, a tumor forms. Until there are signs or symptoms of the tumor, the pregnancy will seem like a normal pregnancy.Most GTD is benign (not cancer) and does not spread, but some types become malignant (cancer) and spread to nearby tissues or distant parts of the body.Gestational trophoblastic disease (GTD) is a general term that
Uterine Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stages IB and IIA Cervical Cancer Treatment
Either radiation therapy or radical hysterectomy and bilateral lymph node dissection results in cure rates of 85% to 90% for women with Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) stages IA2 and IB1 small-volume disease. The choice of either treatment depends on patient factors and available local expertise. A randomized trial reported identical 5-year overall survival (OS) and disease-free survival rates when comparing radiation therapy to radical hysterectomy. The size of the primary tumor is an important prognostic factor and should be carefully evaluated in choosing optimal therapy. For adenocarcinomas that expand the cervix more than 4 cm, the primary treatment should be concomitant chemotherapy and radiation therapy. After surgical staging, patients found to have small volume para-aortic nodal disease and controllable pelvic disease may be cured with pelvic and para-aortic radiation therapy and concomitant chemotherapy. The resection of
Uterine Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Options for Recurrent Endometrial Cancer
Treatment of recurrent endometrial cancer may include the following:Radiation therapy as palliative therapy to relieve symptoms and improve the patient's quality of life.Hormone therapy.Clinical trials of chemotherapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent endometrial carcinoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Uterine Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cervical Cancer During Pregnancy
The size of the primary tumor is an important prognostic factor and should be carefully evaluated in choosing optimal therapy. After surgical staging, patients found to have small volume para-aortic nodal disease and controllable pelvic disease may be cured with pelvic and para-aortic radiation therapy. Five randomized, phase III trials have shown an overall survival advantage for cisplatin-based therapy given concurrently with radiation therapy,[2,3,4,5,6,7,8] while one trial examining this regimen demonstrated no benefit. The patient populations in these studies included women with Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) stages IB2 to IVA cervical cancer treated with primary radiation therapy and women with FIGO stages I to IIA disease who, at the time of primary surgery, were found to have poor prognostic factors, which include the following: Metastatic disease in pelvic lymph nodes.Parametrial disease.Positive surgical margins.Although the
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (06 / 03 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062762-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Prevention